CMS advises Advent International on EUR 4.1bn sale of Zentiva to GTCR
CMS has advised leading global private equity investor, Advent International, on the sale of pharmaceutical company, Zentiva, to Chicago-based private equity firm GTCR, for EUR 4.1bn (USD 4.80bn).
The sale follows a competitive bidding process and will mark a profitable exit for Advent International, which originally bought Zentiva for EUR 1.9bn in 2018. CMS advised Advent International on its initial acquisition of Zentiva, as well as the subsequent acquisition of Alvogen’s CEE business in 2019.
Helen Rodwell, Partner and Head of Corporate and M&A at CMS Prague, comments: “We’re delighted to have advised Advent International on this latest strategic transaction. This deal showcases the strength of the CMS platform, which brings together an integrated group of experts from across our global network to deliver on a complex, high-value and multi-jurisdictional matters such as this.”
The CMS team was led by Helen Rodwell and included Pavel Drimal, Stepan Havranek and Jakub Kabat (CMS Prague); Yavor Danailov (CMS Sofia); Thomas Hirse (CMS Germany); and Jean-Baptiste Thiénot (CMS France).
